Background and aims: This investigation presents a comparison of compartmental modelling with spectral analysis for the kinetic analysis of a radiolabelled anti-cancer drug [ 11 C]temozolomide aiming at resolving inconsistencies in previously reported results. Methods: 15 glioma patients underwent paired dynamic PET scans for 90 mins with [ 11 C]temozolomide on the brain tomograph ECAT 953B. 3D imaging data and arterial plasma input functions were acquired and regions of interest defined for the whole tumour, for a tumour area with high signal (tumour rim) and on contralateral normal brain tissue. Purpose: Two previously published reports analysing these [ 11 C]temozolomide data with spectral analysis found that distribution volumes (VD) and plasma-to-tissue rate constants (K 1 ) could differ as much as an order of magnitude dependent on the treatment of the fractional tissue blood volume. 1, 2 In an attempt to resolve these differences, we have characterised the kinetics of [ 11 C]temozolomide in gliomas and normal brain tissue with reversible compartmental models. Results: Consistent with the previous reports, 1,2 the [ 11 C]temozolomide kinetics in normal brain tissue is adequately described by a one-tissue compartment model with a free blood volume term. In gliomas, an additional exponential was identified with spectral analysis. In line with this, the fit of the tumour tissue-time activity curves with a two-tissue compartment model and a free blood volume term was significantly better than the fit with the one-tissue compartment model.
Population meany
The figure shows mean values with one standard deviation bars for K 1 , VD and the mean residence time of the tracer in tissue (MRT) from our cohort of 15 subjects obtained with compartmental analysis. The population mean values for K 1 are in close agreement with those obtained with spectral analysis in ref. 2 , when the contribution from the blood volume was excluded, and are about an order of magnitude smaller than those in ref. 1, where the blood volume term was erroneously included in the calculation of K 1 . Contrary to the findings of VD normal = 6.97 and VD tumour = 54.4 in ref. 1 , our VD estimates are only slightly smaller than those reported in ref. 2 . Consequently, the MRT estimates for normal tissue are slightly smaller than in ref. 2 , but in contrast to ref. 1 , clearly distinct to those obtained for tumour and tumour rim, respectively. Conclusions: Compartmental modelling provides stable estimates of [ 11 C]temozolomide kinetic parameters compared to spectral analysis due to its ability to constrain the parameter space independent of the choice of a functional base, thus reducing variability. Consistent with earlier reports, 1,2 the increase in K 1 best reflects the activity of the lesion suggesting changes of the [ 11 C]temozolomide blood-brain-barrier penetration in malignant disease. Objectives: Occupancy of dopamine D 2 receptors by antipsychotic drugs can be estimated from reduction in the observed binding potential (BP ND ). Because BP ND varies widely in occupancy studies, accuracy of the measurement of wide range BP ND should be confirmed. The purpose of this study is to investigate errors in quantitative analysis for estimating dopamine D 2 receptor occupancy by antipsychotics with agonist ligand [ 11 C]MNPA which has high affinity and selectivity to dopamine D 2 receptors. 1 Methods: Simulated TACs of [ 11 C]MNPA with several noise levels were generated to investigate the bias and variation of parameter estimates caused by the statistical noise for non-linear least square (NLS) fitting and a simplified reference tissue model (SRTM) methods. A dynamic tracer concentrations was consisted of three target conditions (K 1 = 0.44, k 2 = 0.067, k 3 = 0.02, 0.1 or 0.2, k 4 = 0.18), and a reference (K 1 = 0.44, k 2 = 0.067) with a dynamic frame (20 secs Â 9, 1 mins Â 5, 2 mins Â 4, 4 mins Â 11, 5 mins Â 6, totally 90 mins) and a measured input function from human study. 1 Three true BP ND values were assumed; 1.111 (baseline), 0.556 (occupancy = 50%) and 0.111 (90%). Then Gaussian noise was added at the noise level 1%, 3%, 5%, 7% and 10%, and five hundred noisy data sets were generated for each. 2 The reliability of BP ND estimated by NLS and a SRTM and the calculated occupancy, dependency of scan durations (32, 44, 60, 75 and 90 mins) for SRTM were investigated. Results: For NLS and SRTM methods, the bias of estimated BP ND values became larger as the noise level increased and these bias of BP ND were larger than those of occupancy ( Figures 1A and 1B ). In the case of small BP ND , the bias became larger. For SRTM method, reliable and unbiased occupancy estimates of [ 11 C]MNPA could be obtained by 60 mins with the relative standard deviation remaining less than 10%. However, shorten scan duration depredate the quantification of very small binding potential ( Figure 1C ). Conclusions: Dopamine D 2 receptor occupancy by antipsychotics can be estimated precisely by SRTM method with an optimal scan duration with [ 11 C]MNPA. addressed the comparison between pre-and postsynaptic functions of 5-HT; 1,2 however, these studies are limited in their applicability because of their small sample size. The aim of this study was to investigate the intraindividual relationship between 5-HTT and 5-HT 1A receptors using PET in a relatively large group of normal male subjects. Methods: Dynamic PET scans were performed on 23 young, healthy males with both [C-11]DASB and [C-11]WAY-100635 to measure the binding of 5-HTT and 5-HT 1A receptors, respectively. A 2-parameter multilinear reference tissue model and a reference tissue model were used to calculate the binding potential (BP ND ) of [C-11]DASB and [C-11]WAY-100635, respectively, on a voxel-by-voxel basis, with the cerebellum as the reference region. All PET images were anatomically standardized to the template magnetic resonance image and smoothed with an 8-mm Gaussian filter using SPM2. Furthermore, the volumes-of-interest (VOIs), namely, the raphe nucleus, thalamus, striatum, parahippocampal gyrus, insula, temporal cortex, base of the frontal cortex, and the convexity of the frontal cortex were manually traced on the standardized and smoothed BP ND images. Pearson's coefficient correlation was used to compare the bindings of both the tracers in the same VOIs; corrections for multiple comparisons among VOIs were not performed. Results: The BP ND values of each VOI are presented in Table ( 
Pearson's correlation coefficient indicated significant inverse correlations between BP ND of [C-11] DASB and that of [C-11]WAY-100635 in the insula (r = À0.46, P = 0.028), base side of the frontal cortex (r = À0.47, P = 0.023), and the convex side of the frontal cortex (r = À0.46, P = 0.029). No significant correlation was observed in other regions. Conclusions: The distribution of 5-HTT and 5-HT 1A receptors in the brain was consistent with the findings of post-mortem studies. In addition, we found inverse correlations between BP ND values of 5-HTT and 5-HT 1A in the insula and frontal cortex. These relationships might indicate a complementary nature between 5-HTT and 5-HT 1A functions in such regions. Further investigations are required to elucidate the relationship between the activity of the pre-and postsynaptic serotonergic system in relation to mental functions. Objectives: Positron emission tomography with [ 11 C]raclopride is widely used to investigate the dopamine D 2 receptor system that is related with several neurological and psychiatric disorders in the brain. The dopamine D 2 receptor density (B max ) and affinity (K d ) can be determined using a graphical analysis based on Scatchard plot with PET scans. 1, 2 However, in this estimation, multiple PET scans are required under variable specific activity of administered [ 11 C]raclopride, so that they are often obtained on separate day. To shorten the study period of B max and K d measurement, we have developed a multiple injection simplified reference tissue model (MI-SRTM) that provides the change of binding potential (BP) value from a single session of PET scanning in conjunction with multiple injections of [ 11 C]raclopride. 3 In this study, we established the method for estimating B max and K d with multiple-injection approach, and validated the proposed method by performing numerous simulations and studies on monkeys with PET and [ 11 C]raclopride. Methods: In the simulation studies, to determine the injection protocol of our multiple-injection approach, time-activity curves (TACs) of the striatum and cerebellum were generated using plasma input function and two-tissue compartment 5-parameter model including K 1 , k 2 , k on , B max , and k off for various mass of administered raclopride, and a relation Objectives: Parkinson's disease (PD) is a progressive neurodegenerative disorder. Depression is one of the most disabling co-morbidities associated with PD and both PD and depression are poorly treated in advanced patients. Electroconvulsive therapy (ECT), a form of electric brain stimulation, is one of the most effective therapies used to treat depression and has additional beneficial effects on the motor symptoms of PD. Little is known about the mechanisms of action of ECT in PD patients. Rodent studies do not allow long-term longitudinal studies of regional changes in monoamine neurotransmission and ethical concerns reduce the feasibility of performing extensive longitudinal studies in human PD subjects. The aim of this work is to explore the neural mechanisms underlying the therapeutic effects of ECT, focusing on dopaminergic neurotransmission in the lesioned and unlesioned striatum of non-human primates.
Quantitative assessment of density and affinity for dopamine D 2 receptors with multiple injections of [ 11 C]raclopride

Electroconvulsive therapy induces alterations in dopamine receptor and transporter binding in the striatum of healthy and MPTP-lesioned non-human primates
Methods: The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin was used to induce hemi-parkinsonism (unilateral lesion) in 4 rhesus monkeys and full parkinsonism (bilateral lesion) in 3. Six monkeys were left unlesioned. ECT was performed under anaesthesia using a clinical ECT device. Electrodes were placed bilaterally and 6 ECT treatments were administered over a 3 week period. Animals received a PET scan before the initiation of ECT treatment and then 24 to 48 h, 1 week and 6 weeks after the end of the course of ECT. Monkeys were scanned using SCH23390, a dopamine D1 receptor ligand; raclopride, a dopamine D2 receptor antagonist; and methylphenidate, which binds to the dopamine transporter (DAT). PET data were coregistered to an average MR from 12 different monkeys and binding potentials were determined using the Logan model for the 30 to 60 mins time period of the scan. Left and right sides of each brain region were averaged in unlesioned and bilaterally lesioned monkeys; whereas sides were kept separate for the analysis in unilaterally lesioned monkeys. Results: In unlesioned monkeys, ECT induced a significant increase in dopamine D1 and a decrease in dopamine D2 receptor binding in the striatum. DAT binding increased at 24 to 48 h and 1 week following the final ECT treatment but returned to baseline levels by 6 weeks. In full PD and the lesioned side of hemi-PD monkeys, no effects were observed in DAT binding and, like in unlesioned monkeys, increases in D1 binding were again observed. Decreases were still observed in raclopride binding of D2 receptors in full PD monkeys.
Conclusion: These data are in agreement with studies in unlesioned and parkinsonian rodents showing increases in dopamine D1 receptor binding in response to ECT. Effects of ECT on D2 receptors and DAT have not been previously investigated. Better understanding of the mechanism of action of ECT may lead to refinements in its clinical therapeutic applications in depression and PD.
649. Cognitive function and intelligence related to serotonergic neurotransmission: a brain PET study in young healthy volunteers with 11 C-DASB Results: A positive correlation was found between WNT and BP ND in left caudate (R = 0.586, P = 0.0026, see Figure) , right caudate (R = 0.578, P = 0.0398), left ventrolateral prefrontal cortex (R = 0.495, P = 0.0139), a tendency was found in left dorsolateral prefrontal cortex (R = 0.366, P = 0.0784), but none in putamen. A positive correlation was also found between education years and left caudate (R = 0.438, P = 0.012) and a tendency was found in right caudate (R = 0.526, P = 0.096). No correlations between regional BP ND and DART, specific memory and executive function tests were found. All p-values are uncorrected. Conclusion: Our results showed a positive correlation between SERT binding primarily in the left hemisphere regions and intelligence measured with WNT. This was supported by same the pattern for education years found in caudate. Our results indicate that a putative link between the SERT level and general intelligence must be mediated through other mechanisms than mere memory and executive functions. However, an efficient 5-HT reuptake system seems to be of importance for general intelligence. Background: There is still controversy on the effect of levodopa and dopamine (DA) agonist treatment on Parkinson's disease (PD) progression as evaluated with imaging studies and on their impact on changes in synaptic DA levels. The latter point is of great clinical interest due to the established link between oscillations in synaptic DA levels and propensity to develop treatment-related motor complications. Here we investigated the effect of chronic levodopa and pramipexole treatment on the binding of the 11Cdihydrotetrabenazine (DTBZ) tracer to the vesicular transporter of type 2 (VMAT2), taken as a marker of dopaminergic integrity, and on changes in synaptic levodopa-derived synaptic DA levels (delta (DA) as measured by a double 11C-Racloprice (RAC) scan using the unilateral 6-OHDA rat model of PD. Methods: 28 unilaterally 6-OHDA lesioned rats underwent a DTBZ, and two RAC scans (baseline and 45 mins after I.P. administration of levodopa/ benserazide (50 mg/kg, 15 mg/kg prepared). After being assigned to three degree-of-denervationmatched treatment groups (saline (S, N = 7), pramipexole (PRA, N = 10) and levodopa (LD, N = 11)) and undergoing treatment for approximately 4 weeks, they underwent an identical scanning protocol and imaging measures were compared. Dopaminergic denervation as estimated from the pre-treatment DTBZ scan ranged between 17% and 96%. ANOVA analysis was used to compare pre-and post-treatment results expressed in terms of BP ND for the control and lesioned side respectively. Results: On the control side, no treatment effect was found for DTBZ binding together with a significant overall reduction (P = 0.003). On average the PRA group showed a slightly higher reduction (B7% versus B3% for the other two groups). On the lesioned side a significant treatment effect was observed (P = 0.043) with the PRA group only showing a slight decrease. After adjusting for baseline DTBZ and RAC binding values, a treatment effect (P = 0.018) was observed for delta (DA) on the lesioned side with no change for the PRA and LD treated groups and a trend towards an increase in the S group. On the control side a significant treatment effect was observed (P = 0.032) with a trend toward an increase of delta (DA) in the PRA treated group. Conclusion: The most important finding of this study is that once denervation is present, neither pharmacological treatment changes delta (DA), thus neither treatment should influence the probability of developing motor complications. In addition, it shows that DTBZ might not be an objective marker to accurately monitor disease progression: the fact that a reduction in DTBZ binding on the control side was observed for all treatment groups, including saline, indicates that such reduction likely does not arise as a consequence of a possible treatment-induced terminal damage but rather from competition with DA arising either from increased synthesis (with the corollary that the control side might be susceptible to some of the regulatory changes occurring on the lesion side) or pharmacologically increased availability thus rendering this marker sensitive to either compensatory or pharmacological effects consistently with previous findings. Care must be thus taken when using PET markers to objectively determine either treatment effects or disease progression. A commonly used method for studying relative changes in endogenous dopamine concentration is the two-scan paradigm with [ 11 C]raclopride (RAC). In a 2-scan design, D2 receptor binding potential (BP) during a challenge state is compared to BP estimated from a resting or baseline state. Any detected changes in BP are attributed to changes in striatal dopamine levels. One of the inherent assumptions of this method is that basal dopamine tone is relatively stable in individuals. Indeed, the majority of available literature supports the notion that intra-individual RAC BP is consistent, with most reports citing between-scan differences in baseline BP in healthy subjects of approximately 10%. [1] [2] [3] [4] [5] However, the test-retest variability (TRV) has not been determined for individuals who have a family history of alcoholism (FHA). Objective: The TRV of baseline RAC binding was determined as part of an ongoing study investigating the reproducibility of dopaminergic responses to alcohol. Methods: Data are reported from 7 subjects who underwent 2 baseline RAC scans on separate days. Scan start times were between 1-3:30 p.m. Subjects were male, right-handed smokers who had > 1 blood relative with a history of alcoholism. Three subjects were social drinkers (SD), and 4 were nontreatmentseeking alcoholics (NTS). Subjects received a nicotine patch to prevent craving. Timing and dose of last alcohol exposure were controlled by administering a controlled IV infusion of alcohol 5 h prior to scanning (target breath alcohol concentration (BrAC): 60 mg%; BrAC returned to zero prior to baseline RAC). RAC BP was estimated for right and left caudate, putamen, and ventral striatum using conventional reference region methods. 6 TRV was calculated as |BP 1 ÀBP 2 |/[(BP 1 + BP 2 )/2]. Results: Across all subjects and all regions, the average TRV was very high (19.4±0.04%). There was no consistency in directionality of change in BP between scan days, either across all subjects or between SD and NTS. Exploratory analyses were conducted to identify putative sources of the high TRV. SD subjects had a significantly higher TRV in the left putamen relative to NTS (P < 0.02). Light smokers (r15 cigarettes/day) tended to have greater TRV in the left ventral striatum than heavy smokers ( > 15/day; P = 0.08). The number of alcoholic relatives was significantly correlated with TRV in the left caudate and putamen (n = 7; P < 0.05). There were no interaction effects between smoking and FHA in any region. No variables were associated with TRV in the right striatum; small sample size may have precluded detection of any effects. Conclusions: Striatal DA tone may be highly labile in smokers with a FHA. It is unclear what is contributing to the high TRV in this sample; a larger cohort is needed for more definitive conclusions. These preliminary data suggest that, without knowledge of the TRV in a population, 'negative results' from DA challenge data should be interpreted with caution.
Possible effects of family history of alcoholism on the test-retest variability of striatal D2 availability
The dopamine D2 receptor is of interest for its role in the action of antipsychotic drugs, and therefore its implied role in the pathology of psychotic illness. A linear relationship exists between clinical potency and affinity for D2 receptors for many antipsychotic drugs.
18 F-Fallypride is a high affinity dopamine D2/D3 radioligand used for quantifying striatal but also extrastriatal dopamine D2/D3 receptors with positron emission tomography (PET) and related techniques. We have successfully accomplished the automation of 18 F-fallypride radiosynthesis, purification and formulation. The full synthesis has been accomplished in a total time of 80 mins with a radiochemical yield of 40%. 18 F-fallypride can be obtained with excellent radiochemical purity ( > 96%) and enantiomeric excess (94%), with specific activities of 1 to 3 Ci/mmol.
In the present studies we have used a beta microprobe system to measure 18 F-fallypride binding in the striatum of Sprague-Dawley rats, using the cerebellum as a reference region. For displacement of 18 F-fallypride, the antipsychotic haloperidol was chosen for its high affinity for D2 receptors.
Beta microprobe systems have recently become commercially available as an affordable alternative to PET. These systems utilise implantable probes consisting of a small (0.25 to 1 mm) scintillation crystal bonded to a fibre optic cable, which can be stereotactically located in a specific region of the rodent brain. Scintillation in the crystal is carried by fibre optic to a photomultiplier tube from which a timeactivity curve is generated. 18 F-fallypride was injected intravenously through a catheter in the femoral vein and activity in the striatum and cerebellum measured for 90 mins. After 30 mins a bolus of saline was injected as a control before the injection of haloperidol (0.025 to 0.25 mg/ kg) 30 mins later. Specific striatal binding was calculated as [total binding striatum]-[binding cerebellum]. The effect of saline and haloperidol on specific binding was calculated as the percentage change in specific binding from the 30 or 60 mins maximum.
Haloperidol displaced 18 F-fallypride binding in the striatum in a clear dose-and time-dependent manner. Measurement of binding for a longer duration could be useful to confirm the maximum change in binding after haloperidol treatment. These results confirm the usefulness of the beta microprobe system for the measurement of D2 binding using 18 F-fallypride. the obtain a measure of binding potential (BP ND ) with the cerebellum (CBM) as a reference region using the Logan DVR and MRTM2 methods. Results: In the arterial plasma, both radiotracers cleared from the plasma at a similar rate, with a slow component of 0.0088 and 0.0093 min À1 for MEFWAY and MPPF. The CBM to plasma ratios plateaued at 3:1 for MEFWAY and 1.5:1 for MPPF. Throughout the regions of the brain, MEFWAY revealed significantly higher binding.
Using the ROI data, BP ND was (MEFWAY and MPPF): AC-12 and 3.6, HP-11 and 3.1, RN-3.8 and 1.3, PFC-7.9 and 2.5 with less than 5% difference between the Logan and MRTM2 methods. Stable measurements of MEFWAY BP ND were obtained using less than 90 mins of dynamic data. Conclusions: MEFWAY demonstrates a dramatic improvement as a PET biomarker for the 5-HT 1A site, yielding almost 3-fold increases in BP ND over MPPF. Interestingly, MPPF demonstrated approximately double the BP ND in rhesus monkeys over literature values in humans. 2 Further investigation is required to see if this difference is species or methods specific.
Research support: AA017706, AG030524, AA012277.
Objectives: Microdialysis experiments have shown that drugs of abuse, such as alcohol and cocaine, produce an increase in extracellular dopamine (DA) in the striatum of rats. 1, 2 This study examined if similar changes in striatal DA can be detected in Wistar or P rats using small animal PET. We also sought to establish optimal doses and times for imaging the dopaminergic response to drugs of abuse; we varied the time of IV cocaine administration, the type and mode of anesthesia delivery, and the dose of IP alcohol. We gauged DA release by calculating change in raclopride [RAC] binding potential (BP). Methods: PET images were acquired in drug-naïve male Wistar and P rats. All scans were performed on IndyPETIII (B1 mm FWHM in-plane resolution). Prior to each scan, all animals were anesthetized and secured on a stereotaxic holder. Time activity curves were extracted from the striatum and cerebellum and BPs were calculated as a measure of D 2 receptor availability. 3, 4 Only Wistars were given cocaine and both Wistars and P rats were given alcohol. In cocaine studies, Wistars received up to three 11-C RAC scans (one rest and two cocaine) and were anesthetized with isoflurane or a ketamine/xylazine cocktail. Ket/Xyl boosters were given B20 mins after 11C-RAC injection. These animals received 2.0 mg/kg cocaine intravenously 10 mins ('early cocaine') or 25 mins ('late cocaine') after tracer injection. In alcohol studies, Wistars and P rats received up to three 11C-RAC scans (rest, alcohol, saline) and were anesthetized with isoflurane only. These animals received 3.0 g/kg ethanol (20%v/v), 1.5 g/kg ethanol (15%v/v), or 2.25 g/kg ethanol (15%v/v) IP 5 mins before tracer injection. Venous blood samples were collected from animals 10 mins after tracer injection for determination of blood alcohol content (BAC). Results: There was a significant decrease in BP in Wistars given 3 g/kg ethanol IP, as well as in Wistars under ketamine/xylazine given 2 mg/kg cocaine IV.
There was no significant decrease in BP due to cocaine if Wistars were anesthetized with isoflurane. There was no detectable change in BP in P rats who received IP alcohol at either 1.5 or 2.25 g/kg ethanol. In P rats, decreased BP was positively correlated with BAC (r = 0.78, P < 0.04). In fact, large decreases in BP were observed mainly in rats with BACs above 200 mg%. No significant change in BP was found between rest and saline scans. Conclusions: To maximize detectability of alcoholinduced DA release in the striatum, it may be necessary to achieve BAC levels of at least 200 mg%. Cocaine-induced DA release may be quenched by isoflurane, which would be consistent with work of Votaw et al. 5 Results: MA abuse was associated with a trend for increased baseline D 2/3 -receptor density corresponding to 15%(P = 0.1) and 16%(P = 0.06) in the ventral striatum and globus pallidus respectively and 9% in the dorsal striatum (P = 0.2). Relative to HC, MA had greater amphetamine-induced increases in heartrate, and subjective effects (P < 0.01) together with decreases in [ 11 C]PHNO binding potential slightly above HC value in the ventral striatum (À21% MA versus À13% HC, P = 0.1) and globus-pallidus (À30% MA versus À14% HC, P = 0.04) but not in the dorsal striatum. Conclusion: Contrasting with the current PET/ [ 11 C]raclopride imaging literature, these preliminary [ 11 C]PHNO data suggest increased D 2/3 receptors density and greater apparent DA release in MA users relative to HC. This could be explained by pharmacological differences between the in-vivo binding of [ 11 C]PHNO and [ 11 C]raclopride (consistent with our recent finding in Parkinson's disease, Brain, 2008). Specifically, its in-vivo distribution as well as its higher vulnerability to endogenous DA relative to [ 11 C]raclopride could be related to some degree to its selectivity for D 3 compared to D 2 receptors. We recently introduced multiple strategies ('ntPET') for extracting temporal patterns of brain dopamine (DA) fluctuations from dynamic PET using 11C-raclopride. [1] [2] [3] [4] [5] Each of these modeling and parameter estimation methods yields a collection of time-concentration curves for endogenous DA. When the collection of DA curves is dense (i.e., one curve for every voxel), we can produce images of DA concentration at each time-frame; the 4D data set can be thought of as a volumetric DA 'movie'. Viewing a single slice of the movie or viewing parametric maps that we derive from it can reveal clusters of brain regions whose DA activity is synched to a task performance or other DA-ergic stimulus. Methods: A male subject underwent 3 bolus PET studies. One study was a 'rest' condition, the remaining two were 'task' conditions. The latter two sessions involved an identical right-handed finger-tapping task lasting 10 mins. Once, the task was initiated near the midpoint (25 mins) of the scan session. Another time, the task was initiated near the end (40 mins). Data were processed according to non-parametric ntPET 4 to produce DA movies. We generated mages of the DA peak time at each voxel for each of the two tasks. 5 Finally, we created an image of the time-difference between peak times for 'early' and 'late' tasks, respectively. This image was segmented with a Guassian mixture model 6 to identify clusters of temporally like-responding voxels. Results: The segmented image of time-difference between peaks of DA activity for the two tasks is shown in the Figure for 12 contiguous (axial) striatal slices The units in the image are minutes and the largest cluster of striatal voxels (red) involved in the right-handed task are on the left. The time-difference for the dominant cluster is 14.6 ± 0.08 (SEM) min. Analysis of a control study yielded no clusters of comparable size or contiguity. Conclusion: Given that 'early' and 'late' tasks were identical except for timing, we would expect the DAergic response of voxels involved in execution of the task to be delayed by 15 mins in the late task relative to the early one. This appears to be true of the largest cluster of (primarily contralateral) voxels whose peak activity shifts in time by 15 mins from early to late task performance. We believe our images of DA timing are the first of their kind and may enhance our ability to identify clusters and sequencing responsible for responses to motor and other DA-ergic stimuli such as drugs of abuse. Objectives: Serotonin 5HT 1A receptors have been implicated in aging. Effects of aging on the 5HT 1A receptor have been studied using post-mortem tissue as well as by PET imaging (e.g., Costes et al 1 ). Results have varied from no effect to reductions and observed gender effects. Using the selective 5HT 1A radiotracer 18 F-trans-Mefway 5 we have evaluated postmortem in the aging canine model. Ages of the dogs varied from 1 to 15.4 years (equivalent to B15 to 90 human years). Methods: Radiosynthesis of 18 F-Mefway was carried out with a specific activity of > 2 Ci/mmol. Brain tissue was obtained from the cerebellum (CB) and temporal cortex (COR) of beagle dogs of various ages. Sections (10 mm thick) of the tissue were obtained including the cortex (COR) and cerebellum (CB). Sections were preincubated at room temperature for 15 mins in 50 mmol/L Tris-HCl buffer (pH 7.4). Incubation with 1 to 2 mCi/cc of 18 F-Mefway at 371C took place for 1 h. Nonspecific binding was with 10 mm serotonin. Post incubation, sections were washed twice for 3 mins in cold buffer, submerged quickly in cold distilled water and laid out to dry and exposed to phosphor films. Optiquant imaging software was used to quantify binding to the various cortical layers.
Visualization of dopamine dynamics from PET images
Results: Binding of 18 F-Mefway in the various cortical layers were observed and were in agreement with reported 5HT 1A distribution. 2 Serotonin displaced > 90% of binding. Binding in CB was very low; each animal was used as reference in ratio measurements. In the youngest dog (1 Yr) ratio COR/ CB = 19. Highest binding was in layers I, II (100%) and least in III, IV (31%), similar to that found in humans. Over the age range evaluated, no significant reduction in 18 F-Mefway was observed.
Conclusions: The canine model offers the ability to study aging effects. It has also been studied as a potential animal model for human AD. 3 Further studies are underway in additional old animals. Evaluation of D2/D3 receptors using 18 F-fallypride in the canine model is also underway in order to correlate our findings of aging in humans. 4 Research Supported by NIH R21AG030524. Objectives: In most studies, the association between functional (regional cerebral glucose metabolism) and pathological information (brain amyloid plaque load) have been separately investigated using two different traceres, 11 C-PIB and 18 F-FDG PET in assessment of of Alzheimer's disease (AD). In this study, we investigated the possibility of functional R 1 map (relative flow delivery, K 1 region of interest/K 1 reference region) from PIB PET as alternative functional map in stead of FDG PET. Methods: Thirty eight subjects (8 AD and 12 MCI patients, 18 normal volunteers) underwent dynamic 11 C-PIB PET scans with 90 mins scan duration and 18 F-FDG scans with 30 mins after injection. Parametric images of R 1 for 11 C-PIB PET were generated using multilinear reference tissue models (MRTM2). 1 To compare the brain regions with perfusion and metabolic abnormalities on 11 C-PIB and FDG PET quantitatively, R 1 map and FDG images underwent ztransformation with respect to each normal average and SD. The association of the number of abnormal voxels and mean z-value between R 1 map obtained from PIB PET and glucose metabolism obtained from FDG PET was evaluated in the entire brain excluding cerebellum. Results: Z-values of each group were well reflected the severity of AD. At a z threshold of À2.97 for both R 1 PIB and FDG, the number of abnormal voxels across the entire brain showed a correlation, and the mean z-values of abnormal voxels between them were highly correlated (r = 0.86, P < 0.0001). Conclusions: The relative perfusion obtained from PIB PET was well correlated with those of metabolic abnormality in the entire brain. This study may suggest that a single PIB PET study with R 1 map could provide the sufficient information in the distribution of pathologic and metabolic abnormalities in disease progression.
Results: Figure 1 shows a typical [11C]ABP688 binding study in MTLE patient. Conclusions/relevance: Our finding of reduced mGLUR5 binding in the epileptogenic hippocampus contrast with previous demonstration of hippocampal mGLUR5 upregulation. The discrepancy between our in vivo receptor binding study and the post mortem immunohistochemistry might be explained by abnormalities on mGLUR5 structure and function. It remains to be elucidated whether this is a cause or consequence of the seizures, but we were able to demonstrate that mGLUR5 binding studies can have clinical application in the identification of the abnormal hippocampus in MTLE patients. Study supported by: Savoy Foundation for Epilepsy and the American Epilepsy Society Early Career Physician Scientist Award. Figure 1 [11C]ABP688 BPND was reduced in the epileptogenic hippocampus for left and right MTLE patients (maximum t = 4.74 for left and t = 8.37 for right) as compared to controls. No differences in the contralateral hippocampus were seen. Finally, there was no significant differences on R1 maps.
